HighTide Therapeutics Inc
2511.HK
HKD2.98 -0.67%
Exchange: HKSE | Sector: Healthcare | Industry: Biotechnology
Q4 2024
Published: Dec 31, 2024

Earnings Highlights

  • EPS of $-0.19 increased by 74.4% from previous year
  • Net income of -85.42K
  • "" -
2511.HK
Company 2511.HK

Executive Summary

HighTide Therapeutics delivered a QQ4 2024 quarter with no disclosed revenue, continuing to burn cash as it invests in its metabolic/digestive disease pipeline. R&D investment remained the primary driver of outflows (R&D expenses of 80.775m CNY and G&A of 17.587m CNY, totaling operating expenses of 98.363m CNY). The reported net income of -85.422m CNY and EBITDA of -98.229m CNY reflect the company’s stage as a development-stage biotech prioritizing pipeline progression over near-term profitability. Despite the lack of revenue, the balance sheet remains highly liquid, with 310.75m CNY in cash and equivalents and total liquidity of 490.52m CNY, yielding a net debt position of -232.85m CNY. The current ratio stands at 4.67x, underscoring substantial short-term liquidity to fund ongoing R&D and potential collaborations. Management commentary is not captured in the provided transcript data; as a result, forward-looking targets were not disclosed in QQ4 2024. The valuation metrics reflect a pre-revenue, high-risk, high-burn business, with a PBV of 1.271x and a negative P/E due to the quarterly loss.

Key Performance Indicators

Operating Income
Increasing
-98.36K
QoQ: 0.00% | YoY: 99.96%
Net Income
Increasing
-85.42K
QoQ: 0.00% | YoY: 99.98%
EPS
Increasing
-0.19
QoQ: 0.00% | YoY: 74.41%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2025 0.00 -0.13 +0.0% View
Q1 2025 0.00 -0.13 +0.0% View
Q4 2024 0.00 -0.19 +0.0% View
Q3 2024 0.00 -0.19 +0.0% View